These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 32579506)

  • 1. A Review on the Use of Reversal Agents of Direct Oral Anticogulant Drugs in Case of Gastrointestinal Bleeding.
    Ojetti V; Saviano A; Brigida M; Saviano L; Migneco A; Franceschi F
    Rev Recent Clin Trials; 2020; 15(4):309-320. PubMed ID: 32579506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct (New) Oral Anticoagulants (DOACs): Drawbacks, Bleeding and Reversal.
    Karcioglu O; Zengin S; Ozkaya B; Ersan E; Yilmaz S; Afacan G; Abuska D; Hosseinzadeh M; Yeniocak S
    Cardiovasc Hematol Agents Med Chem; 2022; 20(2):103-113. PubMed ID: 34521332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal strategies in patients treated with direct oral anticoagulants.
    Gressenberger P
    Vasa; 2019 Aug; 48(5):389-392. PubMed ID: 30719950
    [No Abstract]   [Full Text] [Related]  

  • 4. Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data.
    Tummala R; Kavtaradze A; Gupta A; Ghosh RK
    Int J Cardiol; 2016 Jul; 214():292-8. PubMed ID: 27082776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How can we reverse bleeding in patients on direct oral anticoagulants?
    Crowther M; Cuker A
    Kardiol Pol; 2019; 77(1):3-11. PubMed ID: 30338501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct-Acting Oral Anticoagulants and Their Reversal Agents-An Update.
    Kustos SA; Fasinu PS
    Medicines (Basel); 2019 Oct; 6(4):. PubMed ID: 31618893
    [No Abstract]   [Full Text] [Related]  

  • 7. Reversal agents for direct oral anticoagulants: considerations for hospital physicians and intensivists.
    Desai NR; Cornutt D
    Hosp Pract (1995); 2019 Aug; 47(3):113-122. PubMed ID: 31317796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Idarucizumab and Factor Xa Reversal Agents: Role in Hospital Guidelines and Protocols.
    Huisman MV; Fanikos J
    Am J Med; 2016 Nov; 129(11S):S89-S96. PubMed ID: 27569673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of oral anticoagulants, old and new, in major bleeding and the need for urgent surgery.
    Milling TJ; Ziebell CM
    Trends Cardiovasc Med; 2020 Feb; 30(2):86-90. PubMed ID: 30952383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Reversal agents for severe bleeding associated with direct oral anticoagulants].
    Giubilato S; Lucà F; Di Fusco SA; Amico F; Colivicchi F; Gulizia MM
    G Ital Cardiol (Rome); 2022 Oct; 23(10):734-745. PubMed ID: 36169124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct oral anticoagulants: a review on the current role and scope of reversal agents.
    Chaudhary R; Sharma T; Garg J; Sukhi A; Bliden K; Tantry U; Turagam M; Lakkireddy D; Gurbel P
    J Thromb Thrombolysis; 2020 Feb; 49(2):271-286. PubMed ID: 31512202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols.
    Huisman MV; Fanikos J
    Am J Emerg Med; 2016 Nov; 34(11S):46-51. PubMed ID: 27697438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticoagulant Reversal in Gastrointestinal Bleeding: Review of Treatment Guidelines.
    Milling TJ; Refaai MA; Sengupta N
    Dig Dis Sci; 2021 Nov; 66(11):3698-3714. PubMed ID: 33403486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of dabigatran-associated bleeding using idarucizumab: review of the current evidence.
    Giustozzi M; Verso M; Agnelli G; Becattini C
    J Thromb Thrombolysis; 2017 Nov; 44(4):527-535. PubMed ID: 28913672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of direct oral anticoagulants: a practical approach.
    Shih AW; Crowther MA
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):612-619. PubMed ID: 27913536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The incidence of thrombotic events with idarucizumab and andexanet alfa: A systematic review and meta-analysis.
    Rodrigues AO; David C; Ferreira JJ; Pinto FJ; Costa J; Caldeira D
    Thromb Res; 2020 Dec; 196():291-296. PubMed ID: 32949961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Present Knowledge on Direct Oral Anticoagulant and Novel Oral Anti Coagulants and Their Specific Antidotes: A Comprehensive Review Article.
    Biswas S; Bahar Y; Bahar AR; Safiriyu I; Mathai SV; Hajra A; Gupta R; Aronow WS
    Curr Probl Cardiol; 2023 Feb; 48(2):101483. PubMed ID: 36336118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal Agents for Direct Oral Anticoagulants: Understanding New and Upcoming Options.
    Rogers KC; Shelton MP; Finks SW
    Cardiol Rev; 2016; 24(6):310-315. PubMed ID: 27548686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of Direct Oral Anticoagulants: Current Status and Future Directions.
    Weitz JI
    Semin Respir Crit Care Med; 2017 Feb; 38(1):40-50. PubMed ID: 28208197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct oral anticoagulants (DOAC) - Management of emergency situations.
    Lindhoff-Last E
    Hamostaseologie; 2017; 37(4):257-266. PubMed ID: 29582928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.